For investors in Hong Kong

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE00BJT1NW94

NAV
SGD 14.24
As of 2024/04/18

1-Day Change
SGD -0.10 (-0.70%)
As of 2024/04/18

Key investment risks:

The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related

risks. In extreme market conditions, you may lose your entire investment.
The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Less

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
An experienced team of specialists that seeks to understand the science and the business of health care

Fund Details

Asset class	Equities
Product Structure	Irish Investment Company
SFDR Categorisation	Article 8
Inception Date	31 Mar 2000
Base Currency	USD
Fund Assets As of 31/03/24	4.08B
Sector	Morningstar Sector Equity Healthcare
Benchmark	MSCI World Health Care Index
Year End	31-Dec

Information on compliance with EU Sustainability related disclosures can be found here.

Share Class Facts

Distribution Type	Accumulation
ISIN	IE00BJT1NW94
Sedol Code	BJT1NW9
Lipper Code	68541898
WKN Code	A2PFGT
Valoren Code	46796359
Pay Dates	N/A
XD Dates	N/A
Inception Date	11 Mar 2019
Currency Code	SGD
Minimum Initial Investment	2,500.00
Minimum Top Up Amount	-

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Cumulative Performance (%)
As of 2024/03/31

A2 HSGD

	Cumulative
	1MO	3MO	6MO	YTD	1YR	3YR	5YR	Since Inception 2019/03/11
A2 HSGD	1.46	7.66	15.45	7.66	14.07	14.84	50.79	53.20

Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.

Calendar Year Returns (%)
As of 2024/03/31

A2 HSGD

	2023	2022	2021	2020	2019
A2 HSGD	3.79	-5.06	4.64	22.02	13.10

Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.

FEE INFORMATION


Initial Charge	5.00%
Annual Charge	1.50%
Ongoing Charge (As of 2022/12/31)	2.39%

The ongoing charge is calculated using the Packaged Retail Investment Product (PRIIPs) methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.

Please refer to the offering documents for more details on the fees and expenses.

Portfolio

Top Holdings (As of 2024/03/31)

	% OF FUND
Eli Lilly & Co	7.08
UnitedHealth Group Inc	5.87
Novo Nordisk A/S	5.13
Merck & Co Inc	3.64
AstraZeneca PLC	3.57
AbbVie Inc	3.36
Sanofi SA	2.48
Boston Scientific Corp	2.30
Vertex Pharmaceuticals Inc	2.30
Abbott Laboratories	2.26
TOTAL	37.99

Portfolio holdings are subject to change without notice.

Sector
Region

Sector Allocation	% OF FUND	% OF FUND	(As of 2024/03/31)

Regional Allocation	% OF FUND	% OF FUND	(As of March 31, 2024)

About us

Our people

Environmental, Social and Governance (ESG)

Diversity, Equity and Inclusion (DEI)

Filter by asset class

Learn more

Thematic Investing

Explore insights

Global Life Sciences Fund